非酒精性脂肪性肝病全程治疗策略的探讨和建议

doi:10.3969/j.issn.1672-5069.2016.02.002

JOURNAL OF PRACTICAL HEPATOLOGY ›› 2016, Vol. 19 ›› Issue (2): 132-134.doi: 10.3969/j.issn.1672-5069.2016.02.002

• Orignal Article • Previous Articles Next Articles

Suggestions for therapeutic strategy from at the very beginning in patients with nonalcoholic fatty liver disease

Wu Xiening

Departm ent of Gastroenterology, First Affiliated Hospital, Jioatong University, Shanghai 200080

Received:2015-12-24 Online:2016-03-10 Published:2016-03-04

Abstract

Wu Xiening. Suggestions for therapeutic strategy from at the very beginning in patients with nonalcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 132-134.

[1] Farrell GC, McCullough AJ, Day CP. Non-alcoholic fatty liver disease. Wiley-Blackwell Publishing John Wiley & Sons Ltd. 2013: 46-61.
[2] 巫协宁. 非酒精性脂肪性肝炎的发病机制新说:多重打击论及其治疗展望. 中华消化杂志 2014, 34（3）: 206-209.
[3] 巫协宁. 非酒精性脂肪性肝病胰岛素抵抗的发生机制新解及中西医结合治疗的研究. 中西医结合肝病杂志, 2014, 24（5）: 296-298,310.
[4] 巫协宁. 瘦素的生理功能及其在非酒精性脂肪性肝病中的作用. 国际消化病杂志,2014, 34（2）: 75-76.
[5] 巫协宁. 非酒精性脂肪性肝炎的病理变化与其发生机制和姜黄素抗肝纤维化机制. 肝脏, 2014, 19（2）: 134-136.
[6] 巫协宁, 陆伦根. 非酒精性脂肪性肝炎肝纤维化的发生机制及其诊断的生物标志. 肝脏, 2014,19（8）: 629-631.
[7] 巫协宁. 非酒精性脂肪性肝炎肝细胞癌的发病机制. 中华消化杂志, 2015,35（2）: 77-79.
[8] 李红山, 冯琴, 胡义扬,等. 祛湿化瘀方改善脂肪肝大鼠游离脂肪酸代谢的机制. 中医杂志, 2010, 51（3）: 262-264.
[9] 张慧, 胡义扬, 冯琴,等. 祛湿化瘀方对游离脂肪酸诱导的HepG2细胞脂肪沉积和TNFα分泌的抑制作用. 中国中西医结合杂志, 2007, 27（12）: 1105-1109.
[10] 傅永锦, 潘竞锵, 郑琳颖,等. 栀子提取物对脂肪肝大鼠增强胰岛素敏感性及抗脂肪肝作用. 中国医院药学杂志, 2011, 31（11）: 878-883.
[11] Procaccini C, Galgani M, De Rosa V, et al. Leptin: the prototypic adipocytokine and its role in NAFLD. Curr Pharmaceut Desig, 2010, 16（17）: 1903.
[12] 徐可树, 王华, 枫叶进. 非酒精性脂肪性肝病的研究进展. 临床消化杂志, 2004, 16（6）: 275.
[13] Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis, 2010:28（1）: 180-181.
[14] 付景云, 宋滇平. 血清抵抗素与胰岛素抵抗及大血管病变的相关性. 医学综述, 2008, 14: 814-816.
[15] Edwards CR, Hindle AK, Latham PS, et al. Resistin expression correlates with steatohepatitis in morbidly obese patients. Surg Endosc, 2013, 27（4）: 1310-1314.
[16] Zheng P, Ji G, Ma Z, et al. Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways. Am J Chinese Med, 2009, 37（1）: 69-83.
[17] 吴惠春, 张斌. 姜黄素抗肝纤维化机制研究进展. 中国中西医结合杂志, 2013, 33（1）: 135-137.
[18] Tang Y, Zheng S, Chen A. Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology, 2009, 150（7）: 3011-3020.
[19] 巫协宁, 陆伦根. 非酒精性脂肪性肝炎肝纤维化的发生机制及其诊断的生物标志. 肝脏, 2014, 19（8）: 629-630.
[20] Aleffi S, Petrai I, Bertolani C, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology, 2005, 42（6）: 1339-1348.
[21] Ikejima K, Okumura K, Lang T, et al. The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res, 2005, 33（2）: 151-154.
[22] 文彬, 贺松其, 庆杰,等. 鳖甲煎丸对肝纤维化大鼠作用机制研究. 中国中西医结合消化杂志, 2013, 21（11）: 572-575.
[23] 朱丹, 陈芝芸, 王利群,等. 复方鳖甲软肝片对肝纤维化大鼠肝脏低氧诱导因子1α及其下游分子mRNA表达的影响. 中国中西医结合消化杂志, 2012, 20（7）: 293-296.
[24] 吴曼, 范竹萍. 运动类型对代谢相关脂肪性肝病的影响. 国际消化病杂志, 2012, 32（5）: 259-261.
[25] 贺之敏, 应丹央, 夏永红. 非酒精性脂肪性肝病患者肝纤维化指标与血清尿酸水平关系分析. 中国中西医结合杂志,2013, 21（10）: 523-525.

Suggestions for therapeutic strategy from at the very beginning in patients with nonalcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments